secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEPHROS INC (NEPH)
CIK:        0001196298
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001493152-21-018731
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nephros Q2 revenue $2.3M (+44% YoY); net loss improves 35%; acquires GenArraytion, HDF module filed to FDA
--------------------------------------------------------------------------------

- Net revenue $2.3M (+44% YoY); net loss improved 35% to $1.1M; adjusted EBITDA improved 46% to ($0.8M).
- Water filtration segment rev $2.2M (+40% YoY); gross margin 56%; management expects 55-60%.
- Acquired GenArraytion, Inc. in July 2021 to expand PCR testing and pathogen detection capabilities.
- Filed FDA 510(k) for second-generation HDF Assist Module; anticipates clearance later this year for limited commercial launch.
- Cash and equivalents of $8.3M as of June 30, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1196298/000149315221018731/0001493152-21-018731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1196298/000149315221018731/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-018731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer